Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia

BACKGROUND: An individualised risk-stratified screening for prostate cancer (PCa) would select the patients who will benefit from further investigations as well as therapy. Current detection methods suffer from low sensitivity and specificity, especially for separating PCa from benign prostatic cond...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Giskeødegård, Guro F, Hansen, Ailin Falkmo, Bertilsson, Helena, Gonzalez, Susana Villa, Kristiansen, Kåre Andre, Bruheim, Per, Mjøs, Svein A, Angelsen, Anders, Bathen, Tone Frost, Tessem, May-Britt
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2015
Assuntos:
Molecular Diagnostics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4702000/
https://ncbi.nlm.nih.gov/pubmed/26633561
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.411
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados